Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer

To assess the effects of cyclin-dependent kinase (CDK) 4/6 inhibitors in the treatment of patients with hormone receptor-positive advanced breast cancer.

This is a protocol.

Share/Save